Is Amgen Inc. (AMGN) Overvalued?
We dive into why Amgen Inc. (AMGN) could be considered overvalued on 2026-07-14, based on AAII’s Value Score and Grade.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Commentary & Analysis
Is Amgen Inc. (AMGN) Overvalued?
We dive into why Amgen Inc. (AMGN) could be considered overvalued on 2026-07-13, based on AAII’s Value Score and Grade.Jenna Brashear
Is Amgen Inc. (AMGN) Overvalued?
We dive into why Amgen Inc. (AMGN) could be considered overvalued on 2026-07-10, based on AAII’s Value Score and Grade.Tudor Pop
Is Amgen Inc. (AMGN) Overvalued?
We dive into why Amgen Inc. (AMGN) could be considered overvalued on 2026-07-09, based on AAII’s Value Score and Grade.Michael Rose
Is Amgen Inc. (AMGN) Overvalued?
We dive into why Amgen Inc. (AMGN) could be considered overvalued on 2026-07-08, based on AAII’s Value Score and Grade.Rosalio Madrigal
Financial Summary
| Share Statistics | AMGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $209,212.5 | $251.9 | 99% |
|
| Shares Out (Mil) | 544.0 | 50.8 | 89% |
|
| Institutional Ownership | 99.8% | 92.0% | 94% |
|
| Float (Mil) | 538.2 | 40.5 | 86% |
|
| Beta | 0.44 | 0.95 | 25% |
|
| Avg Daily Volume (000s) | 2,687 | 447 | 86% |
|
| Price Change (52-week) |
27.7% | 54.2% | 68% |
|
| Growth | AMGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.6% | 14.0% | 48% |
|
| Net Income (5yr) | 1.2% | (9.8%) | 41% |
|
| EPS (5yr) | 2.9% | 16.3% | 35 |
|
| Dividends (5yr) | 8.3% | 0.0% | 99% |
|
| Cash Flow (5yr) | (73.2%) | (15.6%) | 2% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 28 | 33 | 31 | |
| Current EPS | $5.618 | $22.352 | $23.439 | |
| Month Ago EPS | $5.603 | $22.389 | $23.464 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $5.742 | $22.321 | $23.387 | |
| Year/Year Chg | 68.2% | 57.1% | 71.5% | |
| Financials | AMGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $37,220 | $39 | 95% |
|
| Net Income (TTM) (Mil) | $7,800 | ($43) | 98% |
|
| EPS (TTM) | $14.485 | ($1.600) | 97% |
|
| Operating Cash Flow (TTM) (Mil) | $10,756 | ($30) | 98% |
|
| Net Cash Flow (TTM) (Mil) | $3,228 | $3 | 98% |
|
| Long-Term Debt (Q1) (Mil) | $51,886 | $5 | 98% |
|
| Enterprise Value (Q1) (Mil) | $226,886 | $182 | 99% |
|
| Valuation | AMGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 22.77 | 2.60 | 96% |
|
| P/E | 27.0 | 18.6 | 64% |
|
| Dividend Yield | 2.6% | 0.0% | 81% |
|
| PEG (5yr hist) | 9.3 | 0.9 | 93% |
|
| Ratios | AMGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 71.4% | 63.8% | 82% |
|
| Net Margin | 21.0% | (64.7%) | 80% |
|
| ROA | 8.6% | (49.7%) | 84% |
|
| ROE | 101.3% | (55.4%) | 96% |
|
| Liabilities to Assets | 90.1% | 30.3% | 86% |
|
| F-Score | 8 | 3 | 94% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
O'Shaughnessy: Value Screen
Factors: Yield, Value
Value screen created by James O'Shaughnessy based on his study of a wide range of value approaches.
| Performance Since Inception: | 7.4% |
| +/- S&P 500: | -0.1 |
FACTOR STRATEGY
Dogs of the Dow Screen
Factors: Yield, Value
Identifying contrarian plays among the Dow Jones industrial stocks.
| Performance Since Inception: | 4.2% |
| +/- S&P 500: | -3.3 |
